First slide
Cytocell Logo

Product summary

  • Technology FISH
  • Application Haematology
  • Areas of interest CLL
  • Region 11q22.3
  • Label    
  • Product Code LPH 052 (10 tests)
    LPH 052-S (5 tests)
  • Regulatory Status In vitro diagnostic. This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples. Disease information supported by the literature and is not a reflection of the intended purpose of this product.



Probe specification

  • P53, 17p13.1, Red
  • ATM, 11q22.3, Green

The P53 component consists of a 161kb probe, labelled in red that covers the whole P53 (TP53) gene and flanking regions. The ATM component consists of a 182kb probe, labelled in green that covers the telomeric end of the NPAT gene and the centromeric end of the ATM gene beyond the D11S3347 marker.


Probe information

The tumour suppressor TP53 (tumor protein p53) gene at 17p13.1 and the protein kinase ATM (ATM serine/threonine kinase) gene at 11q22.3, are frequently deleted in cases of chronic lymphocytic leukaemia (CLL).

CLL is the most common leukaemia in adults; its course can vary from very indolent to rapidly progressive. Due to the low mitotic activity of the leukaemic cells in vitro, clonal chromosomal abnormalities are detected in 40-50%2 of cases by conventional cytogenetics using B-cell mitogens, whereas FISH analysis identifies chromosomal aberrations in approximately 80% of CLLs2. Screening for deletions of ATM and/or TP53 is vital to allow informed therapy choices for CLL patients, as deletions of TP53 and ATM confer poorer prognosis in this disease1,2,3.

The TP53 gene is one of most important tumour suppressor genes; it acts as a potent transcription factor with fundamental role in the maintenance of genetic stability. Loss of TP53 is reported in 10% of patients with CLL, and is considered to be the poorest prognostic marker in that disease1,4.

ATM is an important checkpoint gene involved in the management of cell damage; its function is to assess the level of DNA damage in the cell and attempt repair by phosphorylating key substrates involved in the DNA damage response pathway5. Loss of ATM is reported in 18% of patients with CLL, and is considered a poor prognostic marker in that disease2.

Analysis of the ATM/TP53 interaction in CLL has shown that TP53 and ATM play an important role in the proliferation of lymphoid cancer5, it has been shown that ATM enhances the phosphorylation of TP53, should the damage be so great that the cell requires destruction by apoptosis (which is mediated by TP53). Deletion of ATM removes this checkpoint activity and hence activation of TP53. Thus, there is no attempt made to repair, or apoptosis of, damaged cells, despite the presence of TP53. In the absence of ATM, damaged cells are allowed to continue to proliferate6.

What our customers say


  1. Rossi D, et al., Blood. 2013 Feb 21;121(8):1403-12
  2. Dohner et al., N Eng J Med 2000;343:1910-1916
  3. Zent et al., Blood 2010;115(21):4154-4155
  4. Baliakas P, et al., Leukemia. 2014;(April):1-8
  5. Stankovic et al., Blood 2004;103(1):291-300
  6. Khanna et al., Nature Genetics 1998;20(4):398-400

Recommended protocol for CytoCell haematology FISH

Select a protocol step to view:

Sample and slide preparation

1. Sample & Slide Prep Dark Blue
  • Spot the cell sample onto a glass microscope slide. Allow to dry.
  • Immerse the slide in 2x Saline Sodium Citrate (SSC) for 2 minutes at room temperature (RT) without agitation.
  • Dehydrate in an ethanol series (70%, 85% and 100%), each for 2 minutes at RT.
  • Allow to dry.
Haematology FISH protocol Video Image
Play Icon

Haematology FISH protocol

Request a quote for this product

FISH resources & support